Anorexia NervosaNCT02794389
Glutathione Levels and Compulsivity
A study testing N-acetyl cysteine in people with Anorexia Nervosa and Compulsive Behavior, run by University of Oxford at 1 site in United Kingdom.
Trial summary
The investigators will examine whether compulsivity in those who score above-average (but below clinical cut-off) on an eating disorder questionnaire can be altered by 9 days of N-acetyl cysteine (NAC). Read more about this study
- Who is it for?
- Ages 18 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Anorexia Nervosa, Compulsive Behavior
- What is being tested?
- N-acetyl cysteine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 23 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Mar 2016to Apr 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Participant is willing and able to give informed consent for participation in the study.
- Females aged 18 to 40 years.
- Score between 9 and 19 on the EAT-26.
- Participant is a fluent English speaker
Who cannot join
- Any current psychotropic medications.
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the study.
- BMI below 18.5, indicating that they are underweight.
- Any Axis I psychiatric disorder.
- History of allergies to drugs or vaccines or any component of the NAC or placebo capsule (gelatine, magnesium stearate, NAC).
- Pregnant, could be pregnant, breast feeding, or high risk of pregnancy (no reliable contraception use but sexual activity).
Show all 10Show fewer
- Has taken part in a psychological or medical experiment involving taking any kinds of drugs within the last 6 weeks.
- Has had recent surgery.
- Taking selenium, vitamin E, or NAC.
- Current regular cigarette smoking of over 5 cigarettes per day.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Department of Psychiatry, University of Oxford
Oxford, Oxfordshire, OX3 7JX
About this study
Official title: How do Glutathione Levels Affect Compulsivity? A Double-blind, Placebo-controlled Study
The investigators will examine whether compulsivity in those who score above-average (but below clinical cut-off) on an eating disorder questionnaire can be altered by 9 days of N-acetyl cysteine (NAC). N-acetyl cysteine has been shown to be of some benefit in individuals with other compulsive disorders, such as trichotillomania and addiction, so this research investigates whether a short period of time taking N-acetyl cysteine changes compulsivity, measured using cognitive tasks and questionnaires.
Read the detailed description
Anorexia nervosa is a psychiatric disorder with a high mortality rate and for which there is very little evidence for pharmacological interventions of value. The picture is similar in bulimia nervosa, with a high mortality rate and with mixed outcomes from studies testing Selective Serotonin Reuptake Inhibitors (SSRIs). It is possible to conceptualise eating disorders as akin to compulsive disorders, especially noting that repetitive weighing, calorie counting and compulsive exercise and compensatory mechanisms might fit into a hypothetic obsessive-compulsive spectrum (OC spectrum). Some disorders on this OC spectrum are associated with oxidative stress. This may also be true in eating disorders: it has recently been found in a meta-analysis that there is evidence of increased oxidative stress markers in AN.
Glutathione is the main cellular anti-oxidant in mammals and it is possible to increase glutathione levels (and thus potentially combat oxidative stress) with a dietary supplement called N-Acetyl Cysteine (NAC). NAC is an acetylated form of the naturally occurring amino acid cysteine, and is converted to cysteine in the body. Cysteine is a key precursor of glutathione. Oral administration of cysteine itself does not increase brain glutathione levels because cysteine is poorly absorbed from the gastro-intestinal tract. However NAC is bioavailable and thus administration of it does increase glutathione in the brain.
Using NAC to increase glutathione levels has been shown to be beneficial in some compulsive disorders such as addictions, Obsessive-Compulsive Disorder (OCD) and related disorders such as trichotillomania in preliminary studies. There have been positive indications for use and evidence in pathological gambling, trichotillomania, OCD and cocaine addiction. However, NAC has not to our knowledge ever been considered for the treatment of eating disorders. This research therefore aims to investigate whether increasing glutathione can reduce neuropsychological markers of compulsivity in a group at risk for eating disorders.
The researchers have chosen to use a female non-patient group which is thought to be highly compulsive, but which will also be without the possible confounds of medication (as in OCD or addiction disorders) and without malnutrition (as in clinical eating disorders). Those recruited will be females, because there is evidence that there may be different risk factors and thus mechanisms underlying the development of eating disorders in males and females, such that recruiting both might produce a confound. The investigators have also chosen to use a short duration of NAC administration. This not only allows the use of a cross-over design without fears of high attrition rates and non-compliance, but it also will allow the detection of subtle and early changes in compulsivity. The hypothesis is thus that improvements will be seen in tasks measuring compulsivity, and also potentially in tasks which measure related constructs such as impulsivity, habit-based learning, and delay discounting. The researchers do not expect improvement in self-report symptom questionnaires. However, a possible future study would be a randomized clinical trial looking at increasing glutathione in a clinical group over time and how it affects clinical symptomatology.
The questionnaires chosen will identify eating disorder symptom levels (the Eating Attitudes Test - 26 (EAT-26) is a validated way of doing this) and look at compulsive starvation using the self-starvation scale (Godier \& Park 2015). The Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-IV (SCID) will be used to rule out those with a current Axis I diagnosis including an eating disorder, to prevent the complications of starvation and medication in this initial pilot study. The Eysenck Personality Questionnaire (EPQ) will be used to ascertain personality traits, and the National Adult Reading Test (NART) will be used to estimate Intelligence Quotient (IQ).
The rationale for choosing the tasks was based on the hypothesis that compulsivity may be improved by increasing glutathione levels. Thus, the tasks chosen are designed to pick up differences in different facets of compulsivity. The Wisconsin Card Sorting Task (WCST) is able to quantitatively measure set shifting, which is known to be impaired in eating disorders (Roberts et al. 2007) and is a facet of compulsivity. The Affective Go/No go picks up on attention bias within the umbrella of compulsivity; and the Attention Switching task picks up the ability to switch attention between different task demands, within the same compulsivity umbrella. The Cambridge Gambling Task is a good measure of disadvantageous decision making within the umbrella of impulsivity (which is thought to be orthogonally related to, rather than opposite to, compulsivity) (Fineberg et al. 2014). The sequential learning task has been used in OCD, where it is able to disentangle goal-directed learning from habitual learning based on two computational algorithms. The hypothesis is that compulsivity is related to a disturbance in goal-directed learning, with habit learning preferred leading to rigid behaviours (Gillan \& Robbins 2014) (Voon et al. 2015). Thus it will be useful to see if more goal-directed and less habit learning occurs after increases in glutathione levels. The delay discount task measures the ability to ignore delays in time when considering reward value, which is relevant in eating disorders as often delay discounting is reduced so performance is better (Steinglass et al. 2012). This has an interesting interaction with impulsivity as it seems almost to be opposite to it, yet anorexic patients have shown a better performance. Thus this task might be useful as an exploratory measure. The Facial Expression Recognition Task (FERT) is very sensitive to early changes in emotional biases after only small pharmacological changes, and as the profile of individuals high eating disorder symptoms is different in this task compared to healthy controls (Jones et al. 2008) - it can operate as a positive control to identify if increased glutathione is having any effect on general emotional biases, even if it is not on compulsivity.
Because the aim of the study is to see whether NAC may lower compulsivity by increasing glutathione levels, a researcher will take a small venous blood sample (5mls) and a saliva sample prior to testing in both arms of the study to check to what to what extent NAC treatment elevates glutathione levels over placebo. Participants who do not wish to give blood will not be excluded but asked to provide a saliva sample only. Blood and saliva will be rendered acellular by centrifugation and stored until assay in the University Departments of Chemistry and Pharmacology. Once assayed any remaining sample will be discarded according to Standard Operating Procedures for sample disposal.
- Conditions
- Anorexia Nervosa, Compulsive Behavior
- Being tested
- N-acetyl cysteine, Placebo
- Keywords
- Acetylcysteine
- Medical subject headings
- Anorexia Nervosa, Compulsive Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
N-acetyl cysteineDrug
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| N-acetyl cysteine | Experimental | 1200mg for 2 days 2400mg for 7 days Receives: Drug: N-acetyl cysteine |
| Placebo | Placebo comparator | Magnesium stearate capsules Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in scores on the Berg Card-Sort Task (a measure of set-shifting) when taking N-acetyl cysteine compared to placebo
Improvement in scores on the Berg Card-Sort Task (a version of the Wisconsin Card Sorting Task) after NAC compared to placebo. Analyse using paired-sample t-tests on the perseverative error totals for each participant at each visit.
Measured: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
Secondary outcomes (10)
Change in scores on the Attention Switching Task when taking N-acetyl cysteine compared to placebo.
Improvement in scores on the Attention Switching Task after NAC compared to placebo. Analyse using paired-sample t-tests.
Measured: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
Change in score on the Affective Go/No-Go task (measuring attentional bias) when taking N-acetyl cysteine compared to placebo
Improvement in scores on the Affective Go/No-Go task after NAC compared to placebo. Analyse using paired-sample t-tests.
Measured: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
Change in scores on the Cambridge Gambling Task (measuring disadvantageous decision-making) when taking N-acetyl cysteine compared to placebo
Change in scores on the Cambridge Gambling Task after NAC compared to placebo. Compare scores using paired-sample t-tests.
Measured: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
Change in sequential learning task score (a measure of excessive habit-learning) when taking N-acetyl cysteine compared to placebo.
Improvement in scores on the sequential learning task after NAC compared to placebo. Analyse by comparing beta weight of interaction effect between groups (NAC and placebo).
Measured: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
Change in scores on delay discounting task when taking N-acetyl cysteine compared to placebo.
Change in scores on the delay discounting task after NAC compared to placebo. Analyse using paired-sample t-tests.
Measured: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
To examine whether mood symptoms as indexed by the Hospital Anxiety and Depression Scale (HADS) change between baseline, N-acetyl cysteine administration and placebo administration.
Examine scores on HADS and see if they change over those 3 timepoints. Use paired-sample t-tests on the total score on the questionnaire. May also separate the sub-scales for anxiety and depression and perform paired t-tests on these too, if thought necessary.
Measured: Change between screening visit, study visit on the 9th day of taking N-acetyl cysteine, and the study visit on the 9th day of taking placebo.
To examine whether eating disorder symptoms indexed by the EAT-26 change between baseline, N-acetyl cysteine administration, and placebo administration.
Examine scores on EAT-26 and see whether they change over those 3 timepoints. Use paired-sample t-tests.
Measured: Change between screening visit, study visit on the 9th day of taking N-acetyl cysteine, and the study visit on the 9th day of taking placebo.
Examine change in score on the FERT when taking N-acetyl cysteine compared to placebo.
Change in performance on the FERT, analysed using an ANOVA to investigate whether there is an interaction effect in accuracy between emotion recognition and group (N-acetyl cysteine, placebo).
Measured: After 9 days of taking N-acetyl cysteine and after 9 days of taking placebo.
Identify any difference in the side effect profile recorded daily during N-acetyl cysteine administration and placebo administration.
Significantly greater scores on side effect questionnaire during 9 days of NAC vs. placebo. Scores will be derived by totalling all side effects from all 9 days of each arm, with absent corresponding to a score of 0, mild corresponding to a score of 1, moderate corresponding to a score of 2, severe corresponding to a score of 3.
Measured: After 9 days of taking N-acetyl cysteine and after 9 days of taking placebo.
Calculate the percentage of participants who correctly guess which treatment group they are in (N-acetyl cysteine vs. placebo).
Examine the guesses made as to whether NAC/placebo was taken, and calculate percentages correct.
Measured: After 9 days of taking NAC and placebo for each participant.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2016 (estimated)
- Study startMar 2016
- Primary completionApr 2017
- Study completionApr 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Anorexia NervosaStudies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 23 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Phil J Cowen, Prof, Principal investigator, University of Oxford
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02794389
- Sponsor's protocol ID
- R44271/RE001
- Status last verified
- Feb 2018
- First submitted
- 12 May 2016
- Last updated
- 7 Nov 2018
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol. 2010 Nov;20(11):823-8. doi: 10.1016/j.euroneuro.2010.06.018. Epub 2010 Jul 22.
PubMed 20655182Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007 Sep 15;62(6):652-7. doi: 10.1016/j.biopsych.2006.11.021. Epub 2007 Apr 18.
PubMed 17445781Grant JE, Fineberg N, van Ameringen M, Cath D, Visser H, Carmi L, Pallanti S, Hollander E, van Balkom AJ. New treatment models for compulsive disorders. Eur Neuropsychopharmacol. 2016 May;26(5):877-84. doi: 10.1016/j.euroneuro.2015.11.008. Epub 2015 Nov 18.
PubMed 26621260Gillan CM, Kosinski M, Whelan R, Phelps EA, Daw ND. Characterizing a psychiatric symptom dimension related to deficits in goal-directed control. Elife. 2016 Mar 1;5:e11305. doi: 10.7554/eLife.11305.
PubMed 26928075Gillan CM, Otto AR, Phelps EA, Daw ND. Model-based learning protects against forming habits. Cogn Affect Behav Neurosci. 2015 Sep;15(3):523-36. doi: 10.3758/s13415-015-0347-6.
PubMed 25801925Voon V, Derbyshire K, Ruck C, Irvine MA, Worbe Y, Enander J, Schreiber LR, Gillan C, Fineberg NA, Sahakian BJ, Robbins TW, Harrison NA, Wood J, Daw ND, Dayan P, Grant JE, Bullmore ET. Disorders of compulsivity: a common bias towards learning habits. Mol Psychiatry. 2015 Mar;20(3):345-52. doi: 10.1038/mp.2014.44. Epub 2014 May 20.
PubMed 24840709Godier LR, Park RJ. Compulsivity in anorexia nervosa: a transdiagnostic concept. Front Psychol. 2014 Jul 17;5:778. doi: 10.3389/fpsyg.2014.00778. eCollection 2014.
PubMed 25101036Hoffman J, Williams T, Rothbart R, Ipser JC, Fineberg N, Chamberlain SR, Stein DJ. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2021 Sep 28;9(9):CD007662. doi: 10.1002/14651858.CD007662.pub3.
PubMed 34582562
Study at a glance
From the registry record, last updated by the sponsor on 7 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- How do Glutathione Levels Affect Compulsivity? A Double-blind, Placebo-controlled Study
- ClinicalTrials.gov ID
- NCT02794389
- Acronym / sponsor ID
- R44271/RE001
- Conditions
- Anorexia Nervosa, Compulsive Behavior
- Keywords
- Acetylcysteine
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 23 participants (actual)
- Lead sponsor
- University of OxfordUniversity, hospital or other
- Study start
- Mar 2016
- Primary completion
- Apr 2017 (actual)
- Study completion
- Apr 2017 (actual)
- First posted
- 9 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators will examine whether compulsivity in those who score above-average (but below clinical cut-off) on an eating disorder questionnaire can be altered by 9 days of N-acetyl cysteine (NAC). N-acetyl cysteine has been shown to be of some benefit in individuals with other compulsive disorders, such as trichotillomania and addiction, so this research investigates whether a short period of time taking N-acetyl cysteine changes compulsivity, measured using cognitive tasks and questionnaires.
Detailed description
Anorexia nervosa is a psychiatric disorder with a high mortality rate and for which there is very little evidence for pharmacological interventions of value. The picture is similar in bulimia nervosa, with a high mortality rate and with mixed outcomes from studies testing Selective Serotonin Reuptake Inhibitors (SSRIs). It is possible to conceptualise eating disorders as akin to compulsive disorders, especially noting that repetitive weighing, calorie counting and compulsive exercise and compensatory mechanisms might fit into a hypothetic obsessive-compulsive spectrum (OC spectrum). Some disorders on this OC spectrum are associated with oxidative stress. This may also be true in eating disorders: it has recently been found in a meta-analysis that there is evidence of increased oxidative stress markers in AN.
Glutathione is the main cellular anti-oxidant in mammals and it is possible to increase glutathione levels (and thus potentially combat oxidative stress) with a dietary supplement called N-Acetyl Cysteine (NAC). NAC is an acetylated form of the naturally occurring amino acid cysteine, and is converted to cysteine in the body. Cysteine is a key precursor of glutathione. Oral administration of cysteine itself does not increase brain glutathione levels because cysteine is poorly absorbed from the gastro-intestinal tract. However NAC is bioavailable and thus administration of it does increase glutathione in the brain.
Using NAC to increase glutathione levels has been shown to be beneficial in some compulsive disorders such as addictions, Obsessive-Compulsive Disorder (OCD) and related disorders such as trichotillomania in preliminary studies. There have been positive indications for use and evidence in pathological gambling, trichotillomania, OCD and cocaine addiction. However, NAC has not to our knowledge ever been considered for the treatment of eating disorders. This research therefore aims to investigate whether increasing glutathione can reduce neuropsychological markers of compulsivity in a group at risk for eating disorders.
The researchers have chosen to use a female non-patient group which is thought to be highly compulsive, but which will also be without the possible confounds of medication (as in OCD or addiction disorders) and without malnutrition (as in clinical eating disorders). Those recruited will be females, because there is evidence that there may be different risk factors and thus mechanisms underlying the development of eating disorders in males and females, such that recruiting both might produce a confound. The investigators have also chosen to use a short duration of NAC administration. This not only allows the use of a cross-over design without fears of high attrition rates and non-compliance, but it also will allow the detection of subtle and early changes in compulsivity. The hypothesis is thus that improvements will be seen in tasks measuring compulsivity, and also potentially in tasks which measure related constructs such as impulsivity, habit-based learning, and delay discounting. The researchers do not expect improvement in self-report symptom questionnaires. However, a possible future study would be a randomized clinical trial looking at increasing glutathione in a clinical group over time and how it affects clinical symptomatology.
The questionnaires chosen will identify eating disorder symptom levels (the Eating Attitudes Test - 26 (EAT-26) is a validated way of doing this) and look at compulsive starvation using the self-starvation scale (Godier \& Park 2015). The Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-IV (SCID) will be used to rule out those with a current Axis I diagnosis including an eating disorder, to prevent the complications of starvation and medication in this initial pilot study. The Eysenck Personality Questionnaire (EPQ) will be used to ascertain personality traits, and the National Adult Reading Test (NART) will be used to estimate Intelligence Quotient (IQ).
The rationale for choosing the tasks was based on the hypothesis that compulsivity may be improved by increasing glutathione levels. Thus, the tasks chosen are designed to pick up differences in different facets of compulsivity. The Wisconsin Card Sorting Task (WCST) is able to quantitatively measure set shifting, which is known to be impaired in eating disorders (Roberts et al. 2007) and is a facet of compulsivity. The Affective Go/No go picks up on attention bias within the umbrella of compulsivity; and the Attention Switching task picks up the ability to switch attention between different task demands, within the same compulsivity umbrella. The Cambridge Gambling Task is a good measure of disadvantageous decision making within the umbrella of impulsivity (which is thought to be orthogonally related to, rather than opposite to, compulsivity) (Fineberg et al. 2014). The sequential learning task has been used in OCD, where it is able to disentangle goal-directed learning from habitual learning based on two computational algorithms. The hypothesis is that compulsivity is related to a disturbance in goal-directed learning, with habit learning preferred leading to rigid behaviours (Gillan \& Robbins 2014) (Voon et al. 2015). Thus it will be useful to see if more goal-directed and less habit learning occurs after increases in glutathione levels. The delay discount task measures the ability to ignore delays in time when considering reward value, which is relevant in eating disorders as often delay discounting is reduced so performance is better (Steinglass et al. 2012). This has an interesting interaction with impulsivity as it seems almost to be opposite to it, yet anorexic patients have shown a better performance. Thus this task might be useful as an exploratory measure. The Facial Expression Recognition Task (FERT) is very sensitive to early changes in emotional biases after only small pharmacological changes, and as the profile of individuals high eating disorder symptoms is different in this task compared to healthy controls (Jones et al. 2008) - it can operate as a positive control to identify if increased glutathione is having any effect on general emotional biases, even if it is not on compulsivity.
Because the aim of the study is to see whether NAC may lower compulsivity by increasing glutathione levels, a researcher will take a small venous blood sample (5mls) and a saliva sample prior to testing in both arms of the study to check to what to what extent NAC treatment elevates glutathione levels over placebo. Participants who do not wish to give blood will not be excluded but asked to provide a saliva sample only. Blood and saliva will be rendered acellular by centrifugation and stored until assay in the University Departments of Chemistry and Pharmacology. Once assayed any remaining sample will be discarded according to Standard Operating Procedures for sample disposal.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| N-acetyl cysteine | Experimental | Drug: N-acetyl cysteine1200mg for 2 days 2400mg for 7 days |
| Placebo | Placebo comparator | Drug: PlaceboMagnesium stearate capsules |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Participant is willing and able to give informed consent for participation in the study.
- Females aged 18 to 40 years.
- Score between 9 and 19 on the EAT-26.
- Participant is a fluent English speaker
Key exclusion criteria (10 listed)
- Any current psychotropic medications.
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the study.
- BMI below 18.5, indicating that they are underweight.
- Any Axis I psychiatric disorder.
- History of allergies to drugs or vaccines or any component of the NAC or placebo capsule (gelatine, magnesium stearate, NAC).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| N-acetyl cysteine | Drug | N-acetyl cysteine |
| Placebo | Drug | Placebo |
Primary outcome
Change in scores on the Berg Card-Sort Task (a measure of set-shifting) when taking N-acetyl cysteine compared to placebo
Time frame: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
Improvement in scores on the Berg Card-Sort Task (a version of the Wisconsin Card Sorting Task) after NAC compared to placebo. Analyse using paired-sample t-tests on the perseverative error totals for each participant at each visit.
10 secondary outcomes
Change in scores on the Attention Switching Task when taking N-acetyl cysteine compared to placebo.
Time frame: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
Change in score on the Affective Go/No-Go task (measuring attentional bias) when taking N-acetyl cysteine compared to placebo
Time frame: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
Change in scores on the Cambridge Gambling Task (measuring disadvantageous decision-making) when taking N-acetyl cysteine compared to placebo
Time frame: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
Change in sequential learning task score (a measure of excessive habit-learning) when taking N-acetyl cysteine compared to placebo.
Time frame: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
Change in scores on delay discounting task when taking N-acetyl cysteine compared to placebo.
Time frame: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.
To examine whether mood symptoms as indexed by the Hospital Anxiety and Depression Scale (HADS) change between baseline, N-acetyl cysteine administration and placebo administration.
Time frame: Change between screening visit, study visit on the 9th day of taking N-acetyl cysteine, and the study visit on the 9th day of taking placebo.
To examine whether eating disorder symptoms indexed by the EAT-26 change between baseline, N-acetyl cysteine administration, and placebo administration.
Time frame: Change between screening visit, study visit on the 9th day of taking N-acetyl cysteine, and the study visit on the 9th day of taking placebo.
Examine change in score on the FERT when taking N-acetyl cysteine compared to placebo.
Time frame: After 9 days of taking N-acetyl cysteine and after 9 days of taking placebo.
Identify any difference in the side effect profile recorded daily during N-acetyl cysteine administration and placebo administration.
Time frame: After 9 days of taking N-acetyl cysteine and after 9 days of taking placebo.
Calculate the percentage of participants who correctly guess which treatment group they are in (N-acetyl cysteine vs. placebo).
Time frame: After 9 days of taking NAC and placebo for each participant.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Nov 2018.
- Background: PubMed 20655182Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol. 2010 Nov;20(11):823-8. doi: 10.1016/j.euroneuro.2010.06.018. Epub 2010 Jul 22.
- Background: PubMed 17445781Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007 Sep 15;62(6):652-7. doi: 10.1016/j.biopsych.2006.11.021. Epub 2007 Apr 18.
- Background: PubMed 26621260Grant JE, Fineberg N, van Ameringen M, Cath D, Visser H, Carmi L, Pallanti S, Hollander E, van Balkom AJ. New treatment models for compulsive disorders. Eur Neuropsychopharmacol. 2016 May;26(5):877-84. doi: 10.1016/j.euroneuro.2015.11.008. Epub 2015 Nov 18.
- Background: PubMed 26928075Gillan CM, Kosinski M, Whelan R, Phelps EA, Daw ND. Characterizing a psychiatric symptom dimension related to deficits in goal-directed control. Elife. 2016 Mar 1;5:e11305. doi: 10.7554/eLife.11305.
- Background: PubMed 25801925Gillan CM, Otto AR, Phelps EA, Daw ND. Model-based learning protects against forming habits. Cogn Affect Behav Neurosci. 2015 Sep;15(3):523-36. doi: 10.3758/s13415-015-0347-6.
- Background: PubMed 24840709Voon V, Derbyshire K, Ruck C, Irvine MA, Worbe Y, Enander J, Schreiber LR, Gillan C, Fineberg NA, Sahakian BJ, Robbins TW, Harrison NA, Wood J, Daw ND, Dayan P, Grant JE, Bullmore ET. Disorders of compulsivity: a common bias towards learning habits. Mol Psychiatry. 2015 Mar;20(3):345-52. doi: 10.1038/mp.2014.44. Epub 2014 May 20.
- Background: PubMed 25101036Godier LR, Park RJ. Compulsivity in anorexia nervosa: a transdiagnostic concept. Front Psychol. 2014 Jul 17;5:778. doi: 10.3389/fpsyg.2014.00778. eCollection 2014.
- Derived from this study: PubMed 34582562Hoffman J, Williams T, Rothbart R, Ipser JC, Fineberg N, Chamberlain SR, Stein DJ. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2021 Sep 28;9(9):CD007662. doi: 10.1002/14651858.CD007662.pub3.
- Individual participant dataSharing planned: Undecided
Related trials for Anorexia Nervosa
Active, not recruiting
Neuroscience-informed Treatment to Remotely Target Reward Mechanisms in Post-acute Anorexia Nervosa
Anorexia Nervosa
Recruiting
Specialist Supportive Clinical Management (SSCM) for Children and Adolescents With Anorexia Nervosa and Atypical Anorexia Nervosa
Anorexia Nervosa, Atypical Anorexia Nervosa
Not yet recruitingPhase 2
An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa
Anorexia Nervosa
Recruiting
Influence of Control Deprivation on the Use of the Analytical Cognitive Style in Anorexic Subjects
Anorexia Nervosa
Active, not recruiting
A Study on the Effects of Combined FMT on Gut Microbiota and Eating Disorder Symptoms in AN
Anorexia Nervosa
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Phil J Cowen, Prof principal investigator
University of Oxford
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing N-acetyl cysteine in people with Anorexia Nervosa and Compulsive Behavior, run by University of Oxford at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in scores on the Berg Card-Sort Task (a measure of set-shifting) when taking N-acetyl cysteine compared to placebo (time frame: Change between study visit on the 9th day of taking NAC, and the study visit on the 9th day of taking placebo.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02794389, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2018.